Related Experiment Video
Updated: May 18, 2026

Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Leflunomide: friend or foe for systemic lupus erythematosus?
Guo-Cui Wu1, Xiao-Di Xu, Qiong Huang
1Department of Pharmacy, Binhu Hospital, The First People's Hospital of Hefei City, Lakeshore New District, Hefei 230001, Anhui, China. gcwu82@126.com
Abstract:
Leflunomide is a new immunosuppressive medicine that has been effectively used in the therapy of rheumatoid arthritis and subsequently used with success in animal models and patients with systemic lupus erythematosus (SLE). However, its use has also been associated with significant and serious adverse reactions involving hematological, hepatic, immune, dermatological and respiratory systems. In the current review, we attempt to describe the two sides of this drug in the treatment of SLE.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inhibitors of Viral Protein Synthesis
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome I : Introduction
